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ABSTRACT
Glioblastoma presents as a heterogeneous disease with poor prognosis despite 
the use of multimodal therapy. Analysis of genomic DNA changes between initial 
diagnosis and recurrence in response to standard treatment protocols would enhance 
understanding of disease progression and better inform new treatment strategies. A 
cohort of 21 patients with primary glioblastoma were examined between diagnosis 
and first recurrence. This study presented a rare opportunity to characterize molecular 
alterations in tumors observed in three patients who received no therapeutic 
intervention, other than surgery, offering a unique control. We focused this study 
by comparing the dynamic mutation profiles between the primary tumors and their 
matched recurrent counterparts. Molecular profiling of tumors was performed using 
multiplexed targeted deep sequencing of 409 well characterized cancer-associated 
genes, achieving a mean read depth of 1272 x. Three levels of evidence suggested 
an evolutionary pattern consistent with a response to therapy-mediated selection 
pressures exists in treated patients: 1) variant burden was reduced in recurrent 
tumors, 2) neutral evolutionary dynamics apparent in untreated tumors shifted 
toward a non-neutral mode of evolution in treated patients at recurrence, and 3) the 
recurrent tumor of one patient displayed an increased mutation rate attributable to 
a temozolomide-associated hypermutator phenotype. Our observations suggest that 
current treatment modalities are likely to fail in achieving long term remission with 
the majority of relapse samples containing distinct mutations when compared to 
primary diagnostic samples. 
                          Research Paper
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INTRODUCTION
Fundamental knowledge of the biology of recurrent 
glioblastoma (GBM) has been limited until recently. 
This has been due to the comparatively low numbers 
of patients (20–30%) undergoing surgery at recurrence 
due to limited evidence of clinical benefit [1, 2], thus 
limiting opportunities for molecular characterization 
of the processes associated with disease resistance and 
recurrence. 
In the setting of low grade glioma, hypermutation 
induced by temozolomide (TMZ) treatment was 
observed in a subset of astrocytomas at recurrence [3]. 
Temozolomide-associated mutations were identified that 
target the retinoblastoma tumor suppressor (RB) pathway, 
activate AKT-mTOR signaling and promote tumor growth 
and metastasis. Interestingly, microdissection revealed that 
these mutations were confined to regions with mTORC1 
activation and high Ki-67 index, suggesting that mutations 
induced by TMZ conferred a growth advantage. Whether 
these observations are transferable to primary GBM 
remains to be explored.
Using data from The Cancer Genome Atlas (TCGA) 
and 21 paired primary and recurrent GBM, Kim et al. [4] 
inferred two models for clonal evolution at recurrence. 
In the ancestral cell origin model, dominant clones in 
the primary tumor disappear in response to therapy. New 
mutations are then acquired in refractory ancestral cells 
causing cell proliferation and tumor recurrence. In the 
clonal evolution model, major primary disease clones 
survive treatment and continue to grow. Critically, it 
was found that key alterations in GBM driver genes 
frequently present in primary tumors were unlikely to 
be initiating mutations as they were often absent in the 
recurrent tumor, mutated at a different base or deleted/
amplified with different copy number breakpoints 
suggesting “intratumoral evolutionary pressures resulting 
in convergent evolutionary events”. This emphasizes 
the importance of detailing the characteristics of disease 
relapse in order to better understand the true ancestral 
alterations driving GBM development and identify 
potential therapeutic targets.
Wang et al. [5] analyzed longitudinal genomic and 
transcriptomic data from 114 patients, including a mix 
of primary and secondary GBM initial and recurrent 
tumor pairs. A highly branched evolutionary pattern was 
observed in which 63% of patients exhibited different 
expression-based subtypes at diagnosis and relapse. 
Hypermutation of highly expressed genes was detected 
in 15% of tumors at relapse, with a clear mutational 
signature.
Neutral tumor evolution describes the distribution 
of variant allele frequencies (VAFs) within a tumor and 
predicts that, although individual subclones possess unique 
mutational patterns, they expand at similar rates and 
accumulate linearly with the inverse of their frequency, 
hence following a 1/f power-law distribution [6]. Clonal 
selection appears to have occurred as an early event 
prior to tumor growth and the acquisition of numerous 
passenger mutations results in intratumoral heterogeneity. 
The contrasting notion is that expansion of subclones is 
influenced by strong selection pressures to adapt to the 
tumor microenvironment or in response to treatment 
modalities. The concept of neutral tumor evolution has 
not been examined in detail in GBM.
In the current study we have explored a well-
defined group of clinically annotated primary GBM tumor 
samples to examine the natural history of mutational 
alterations within tumors during progression and in 
response to treatment. Our results emphasize the inherent 
heterogeneity of primary GBM at a genomic level and 
show that GBM is an evolving tumor with or without 
therapeutic intervention. We explored the concept of 
“effectively-neutral” evolutionary dynamics in the context 
of untreated and treated primary GBM, showing a shift 
toward non-neutral evolutionary expansion of subclonal 
variants after treatment with radiochemotherapy. 
RESULTS
Sample characteristics
Our study focused on a group of 21 patients 
(cohort 1) diagnosed with primary GBM, including two 
glioblastoma with primitive neuronal component (GBM-
PNC) histology at diagnosis. Within this cohort, three 
patients had elected not to receive any intervention other 
than surgery and the remaining 18 patients received 
standard concomitant RT and TMZ [7]. Twelve of 
the treated patients then received four to six cycles 
of adjuvant TMZ and three received varied adjuvant 
therapy as described in Table 1. A variety of treatments, 
including carmustine, carboplatin and bevacizumab were 
administered as salvage therapy to some patients after the 
second surgical resection.
Mutational and key pathway analysis 
Specimens from cohort 1 exhibited a pattern of 
variants in coding regions previously well described for 
primary GBM [8, 9]. As matched normal specimens were 
unavailable for this cohort, variant calls may include low 
frequency and rare single nucleotide polymorphisms 
(SNPs). The signaling pathways with nonsynonymous or 
splice site variants detected in key genes are summarized 
in Figure 1, along with MGMT methylation status. 
Specifically, in their initial tumors, non-synonymous and 
splice site variants in EGFR occurred in four patients 
(19%) and eight patients (38%) harbored PTEN variants, 
38% of which were single nucleotide variations (SNVs) 
resulting in premature stop codons and protein truncation 
(p.R130*, p.R223*, p.R335*). The overall incidence of 
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TP53 variants was 33%, detected in seven patients who 
each possessed distinct SNVs. These were all found to 
be annotated in the Catalogue of Somatic Mutations in 
Cancer (COSMIC) [10]. 
Of significant interest were variants in the mismatch 
repair (MMR) pathway that occurred in 52% of patients in 
one or both samples. We observed that in the patients who 
received RT and TMZ, variants present in MSH2, MSH6, 
PMS1 or PSM2 at diagnosis were also present at recurrence 
(Figure 1). Similarly, one of three untreated patients had a 
variant in MSH2 that was also present at recurrence. There 
were no MMR pathway variants unique to diagnosis in 
any patient and no variants unique to recurrence in the 
untreated patients. In contrast, in treated patients a number 
of private variants appeared at recurrence in MLH1, MSH6 
and PSM2, generally at a frequency of less than 30% 
suggesting the emergence of subclones in this pathway 
undetected at diagnosis. Although there was no significant 
difference in the number of variants detected in key MMR 
genes in treated and untreated patients overall, the sample 
in which the variants occurred was noteworthy and was 
a factor that approached statistical significance (F2, 59 = 
3.13, p = 0.051). More specifically, the absence of MMR 
variants unique to diagnosis, compared to the numbers 
present in both samples or uniquely at relapse, fell just 
beyond statistically significant parameters using post-hoc 
tests (t(20) = -2.29, p = 0.065 and t(20) = 2.03, p = 0.113 
for shared and unique to relapse comparison respectively; 
Supplementary Figure 1A). 
In the case of IDH1 we identified six patients with 
variants common to both their diagnosis and relapse 
samples, none of which were the well characterized 
activating substitution at arginine 132 (IDH1R132H+) 
seen in lower grade tumors. Given that somatic IDH1 
variants exclusively alter R132 in GBM as presented in 
TCGA, these detected variants are likely low frequency 
or rare SNPs. In this cohort we identified a missense 
c.548 A > G SNV in Patient 1 (Untreated) and Patient 
3 (Treated), resulting in a p.Y183C amino acid change 
predicted as functionally damaging or deleterious using 
Sorting Tolerant from Intolerant (SIFT) [11] or Protein 
Variation Effect Analyzer (PROVEAN) [12] scores 
respectively. This variant is recorded in the NCBI SNP 
database (dbSNP rs34599179) as a rare SNP with a minor 
Table 1: Summary of patient clinical data
Patient Gender Age at 
diagnosis 
(years)
Primary 
diagnosis
Diagnosis of 
recurrence
Treatment prior to second surgery Time to 
recurrence 
(months)
Survival 
(months)
1 F 50 GBM GBM none 19 36.4
2 F 44 GBM GBM Concomitant RT/TMZ only 3 22.0
3 M 49 GBM GBM Concomitant RT/TMZ and 4 cycles adjuvant TMZ 8 9.9a
4 M 35 GBM-PNC GBM Concomitant RT/TMZ and standard adjuvant TMZ 11 12.2
7 F 62 GBM GBM Concomitant RT/TMZ and standard adjuvant TMZ 7 11.9
8 M 33 GBM GBM Concomitant RT/TMZ and standard adjuvant TMZ 9 18.6
9 M 51 GBM GBM Concomitant RT/TMZ and adjuvant AVAglio (+/-BVZ) 9 16.4
10 M 57 GBM GBM Concomitant RT/TMZ and 2 cycles adjuvant AVAglio (+/-BVZ) 5 17.1
11 M 74 GBM GBM Concomitant RT/TMZ only 3 7.2
12 M 66 GBM GBM Concomitant RT/TMZ and standard adjuvant TMZ 11 15.9
14 M 56 GBM GBM Concomitant RT/TMZ and standard adjuvant TMZ 14 17.6
15 F 33 GBM GBM Concomitant RT/TMZ only 8 14.6
16 M 39 GBM GBM Concomitant RT/TMZ and 4 cycles adjuvant TMZ 9 14.5
18 F 63 GBM GBM Concomitant RT/TMZ and standard adjuvant TMZ 7 14.3
19 M 67 GBM GS Concomitant RT/TMZ and standard adjuvant TMZ, then 2nd line BVZ 8 months 18 19.5
20 F 57 GBM GBM Concomitant RT/TMZ and 9 cycles adjuvant AVAglio (+/-BVZ) 15 19.3
21 F 48 GBM-PNC GBM-PNC Concomitant RT/TMZ and standard adjuvant TMZ 24 29.2
22 M 43 GBM GBM Concomitant RT/TMZ and 4 cycles adjuvant TMZ 10 15.1
26 M 66 GBM GBM Concomitant RT/TMZ and standard adjuvant TMZ 8 30.6
28 M 54 GBM GBM none 2 13.2
29 M 34 GBM GBM none 3 13.8
GBM Glioblastoma; GBM-PNC Glioblastoma with primitive neuronal component; GS Gliosarcoma; BVZ bevacizumab;
AVAglio Phase 3 trial of BVZ plus TMZ and RT in newly diagnosed GBM
aCensored
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allele frequency (MAF) of 0.36%. Patients 14, 15, 16, 26 
(All Treated) each had a c.532 G > A (p.V178I) missense 
variant predicted to be tolerated/neutral. This is classified 
as a low frequency SNP (rs34218846; MAF=4.93%) 
and is present in COSMIC (COSM97131), confirmed as 
somatic for thyroid and lymphoid studies [13]. To date a 
functional role remains unclear. There was also a deletion 
in the 5’ splice site of exon 9 (NG_023319.2:g.28927delC) 
in Patient 15, a rare SNP (rs533101765) with a MAF of 
0.08%. 
Methylation of MGMT was detected in the primary 
tumors of five patients and the methylation persisted at 
recurrence in four of these patients. An additional patient 
was MGMT methylated uniquely at recurrence (Figure 1). 
Only one recurrent patient sample (patient 21) showed a 
pattern consistent with the MMR-defective hypermutator 
phenotype [14–17]. Similar to previous reports, MGMT 
was methylated and multiple DNA MMR genes (MLH1 
and PMS2) were mutated in the recurrent tumor, but these 
variants were not present at diagnosis. Variants in IDH1 or 
IDH2 were not detected in this patient (Figure 1).
In primary GBMs standard radiochemotherapy 
did not impact the burden of mutations in 
recurrent tumors with the exception of one 
patient
When considering the total burden of genetic 
variation detected, including intronic, splice site, non-
synonymous and synonymous exonic variants (patient 
21 was excluded as an outlier; p ≤ 0.001), in treated 
patients there was an average of 120 variants detected in 
newly diagnosed and 103 variants in recurrent samples. 
We found an average of 49 variants to be unique to 
diagnosis and 32 to be unique to recurrence. In the three 
untreated patients a similar pattern of mutational burden 
was observed with an average of 117 and 115 variants 
detected in diagnosis and recurrence samples respectively. 
An average of 37 variants were unique to diagnosis and 35 
were unique to recurrence (Figure 2A). In contrast, patient 
21 was found to have 54 variants unique to diagnosis and 
142 unique to the recurrent tumor (Figure 2A). Excluding 
patient 21, the mean number of variants was significantly 
Figure 1: Patterns of mutations in key signaling pathway genes were consistent with previously described traits of 
primary GBM. OncoPrint summarizing the non-synonymous and splice site variants detected by targeted deep sequencing in both 
diagnostic (open circles) and relapse (closed circles) specimens for each of the 21 patients. Specimens with methylation of MGMT are 
noted in red.
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higher in diagnosis samples compared to relapse (F1,37 = 
6.44, p = 0.016) and there was no significant difference 
between the treated and untreated patients (F1,37 = 0.22, p 
= 0.641; Figure 2B). The number of variants observed also 
varied by sample type (F2,56 = 52.87, p < 0.001), with a 
significantly higher number of variants found to be shared 
between matched samples than unique to either sample 
(t(19) = 6.36, p < 0.001 and t(19) = 10.18, p < 0.001 for 
unique to diagnosis and unique to relapse comparison 
respectively), which may in part be due to the presence of 
low frequency or rare SNPs. Moreover, the mean number 
of variants unique to relapse was also significantly lower 
than those unique to diagnosis (t(19) = 3.82, p = 0.001). 
There was no observable effect of treatment on this pattern 
of variants (Supplementary Figure 1B, 1C; Supplementary 
Table 1). 
Considering only coding region variants that were 
non-synonymous and splice site variants and therefore 
of potentially more functional significance (Figure 2C; 
Supplementary Table 1; Supplementary Table 2), once 
again no difference in variant burden was observed 
between treated and untreated patients (F1,37 = 0.00, p = 
0.996), again with the exclusion of patient 21. Significantly 
fewer variants were detected at recurrence (F1,37 = 14.28, p 
= 0.001; Figure 2D). The mean number of variants unique 
to relapse remained lower than those unique to diagnosis 
(t(19) = 5.64, p < 0.001) and again there was no observable 
effect of treatment (Supplementary Figure 1D, 1E).
In line with recent data [4], the presence of non-
synonymous TP53 variants was associated with a higher 
incidence of low frequency (VAF < 0.4) SNVs in recurrent 
tumors (F1,38 = 21.73, p < 0.001; Figure 2E). Tumors 
were designated TP53 mutated if they possessed a non-
synonymous variant that was predicted to be damaging/
deleterious by SIFT/PROVEAN. All of these variants 
were also previously confirmed as somatic in other 
glioma tumor samples presented in COSMIC. There was 
no significant difference between TP53 wildtype and 
mutant tumors at diagnosis, however, the disproportionate 
variant numbers overall between primary and recurrent 
specimens was not observed in TP53 mutated tumors and 
was confined to low frequency variants in TP53 wildtype 
tumors (Figure 2E; Supplementary Figure 1F). These 
effects were not evident for high frequency variants (VAF 
≥ 0.4) (Figure 2E; Supplementary Figure 1G). 
Treatment with TMZ was found to have little 
effect on the generation of sequence variation in 
recurrent GBM. 
A recognized signature of TMZ-induced 
mutagenesis is the production of C > T/G > A transitions, 
predominantly occurring at CpC and CpT dinucleotides. 
Analysis of the distribution of single base substitutions 
unique to recurrence across all patients revealed a 
higher number of C > T/G > A base transitions overall 
(F1,113 = 3.98, p = 0.002; Figure 3A). However, no clear 
difference was identified when comparing untreated to 
treated patients after adjusting for the type of single base 
substitution (F1,113 = 1.85, p = 0.176; Figure 3B). 
We observed TMZ treatment-induced 
hypermutation, previously described in secondary 
GBM [3, 18], in the recurrent tumor of only patient 21. 
Approximately 72% of the SNVs identified at recurrence 
were classified as TMZ-associated C:G > T:A variants 
unique to relapse and 73% of these occurred at CpC 
and CpT dinucleotides, characteristic of TMZ-induced 
hypermutation (Supplementary Table 3). Review of the 
pathology status did suggest this patient was histologically 
distinct as a GBM-PNC and the patient survived for an 
extended period of 29 months.
In these analyses we compared the total number and 
proportions of each dinucleotide context of these variants 
(Figure 3C; Supplementary Table 3) and, excluding patient 
21, we could not discern any enrichment for these TMZ-
associated transitions in any patient.
Neutral tumor evolution was prominent in 
untreated GBM and a shift toward non-neutral 
evolutionary dynamics was evident in subclones 
after treatment.
Leukocytes unmethylation to infer tumor purity 
(LUMP) analysis, as detailed previously [19], was 
undertaken for 20 of the matched samples in cohort 
1 (patient 12 was excluded due to sample quality 
limitations). A sample purity threshold of 55% excluded 
seven diagnosis and six recurrent samples, which included 
three of six specimens from untreated patients (Figure 
4A; Supplementary Table 4). To account for the potential 
confounding effects of purity, the VAFs detected in the 
remaining specimens were corrected to adjust for varying 
levels of normal tissue contamination [6]. 
Neutral evolution was evident in the tumors of 
patients at diagnosis when subclonal variants and their 
frequency were analyzed collectively. As predicted by 
the neutral evolution model, the cumulative distribution 
of subclonal variants was found to be linear with the 
inverse of their frequency. A strong fit to the neutral 
evolution model with an R2 value of 0.9897 (Figure 
4B) was observed overall for primary tumors and a 
shift to non-neutral evolutionary dynamics was seen at 
recurrence (R2 = 0.9571), suggesting that the selective 
pressures of radiochemotherapy influenced subclonal 
variant expansion. Excluding the relapse sample of 
patient 21 from this analysis, due to its TMZ-associated 
hypermutated status, resulted in a slight increase in 
the goodness-of-fit for the neutral evolution model at 
recurrence (R2 = 0.9602; Figure 4B). A non-neutral 
evolutionary dynamic persisted suggesting that selection 
pressures at recurrence in treated patients were not unique 
to the MMR-defective hypermutator phenotype. 
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Figure 2: The burden of mutations was not heavily impacted by treatment with RT and TMZ. (A) The number of variants 
detected overall in untreated and treated patients, presented according to the specimen/s in which they were observed. (B) Box plot showing 
the mean number of variants by treatment or sample type. Patient 21 was excluded as an outlier from this analysis. (C) Coding region 
variants defined as non-synonymous and splice site mutations, presented as shared or unique to either diagnosis or relapse specimens. 
(D) Box plot showing the mean number of non-synonymous and splice site variants by treatment (treated vs untreated) or sample type 
(diagnosis vs relapse). Patient 21 was excluded from this analysis. (E) The presence of SNVs was analyzed according to the TP53 status of 
tumor specimens. TP53 wildtype tumors (WT) were compared to TP53 mutant tumors (mut), which were defined as those that contained 
non-synonymous TP53 variants. SNVs were designated low VAF (< 0.4) or high VAF (≥ 0.4) and were tallied separately for the diagnosis 
and relapse specimens of each patient (excluding the relapse sample of patient 21). Untreated patients are depicted as open squares and 
treated patients as closed circles. The mean and 95% confidence intervals are also shown. A two-way analysis of variance was performed 
using a general linear model and p-values for significant differences (p ≤ 0.001) are displayed.
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Due to the targeted nature of this high-depth 
sequencing analysis, goodness-of-fit measures using 
the stringent threshold of R2 > 0.98 for defining neutral 
evolution in individual specimens may undercall neutrality 
as low numbers of variants with which to fit the model 
may lead to a poorer fit to the data [6]. In addition 
to discriminating between neutral and non-neutral 
evolution in primary tumors, we were able to compare 
the dynamics of subclonal variants between diagnosis 
and first recurrence, reflecting treatment influences. 
Determination of individual goodness-of-fit measures for 
each sample showed that in paired diagnosis and relapse 
specimens from the same patient the neutral evolution 
model fit decreased in 8 of 10 patients (Figure 4C). 
Subclonal variants in 5 of 13 primary tumor specimens 
achieved R2 values above 0.96. The mean R2 value of 
samples at diagnosis was not significantly different 
from an R2 value of 0.96 (M = 0.9477, 95% CI [0.9314, 
0.9640], t(12) = -1.65, p = 0.125). Whilst collectively 
primary samples displayed effectively-neutral evolution, 
analysis of specimens individually failed to designate 
any samples as evolving neutrally. The mean R2 value 
obtained for patients at diagnosis was significantly lower 
than the stringent R2 threshold of 0.98 (t(12) = -4.832, p 
= 0.001). In contrast to diagnostic samples, the mean R2 
value of relapse samples was significantly lower than an 
R2 value of 0.96 (M = 0.89654, 95% CI [0.8494, 0.9414], 
t(12) = -3.06, p = 0.01). At recurrence, all 13 samples 
were classified as undergoing non-neutral evolutionary 
expansion of subclonal variants. A further shift away from 
a neutral model fit was evident in the majority of samples 
at recurrence with significantly higher R2 values observed 
for diagnosis compared to relapse specimens (F1,24 = 5.06, 
p = 0.034; Figure 4D). Excluding the recurrent sample 
of patient 21 does not substantially alter the significance 
of the difference observed between samples at diagnosis 
and relapse (F1,23 = 4.89, p = 0.037). Neutral evolution of 
subclonal variants was evident in the primary tumor of 
Patient 21 (R2 > 0.9783). However, in the recurrent tumor 
with TMZ-associated hypermutation non-neutral dynamics 
dominate (R2 > 0.9077; Figure 4E). These observations 
suggest that radiochemotherapy exerts selective pressure 
influencing subclonal variant dynamics in treated tumors.
In an attempt to verify these observations in a 
larger cohort, publicly available tumor datasets were 
interrogated for purity and VAF information. Two sets 
of data were analyzed which included selected samples 
(cohort 2) from TCGA [20] and additional samples (cohort 
3) previously collated and reported by Wang et al. [5]. 
A total of 408 samples from TCGA were considered, 
including 12 recurrent specimens. Of these, 175 were 
evaluated for neutral tumor evolution with data from 93 
primary samples satisfying final inclusion criteria for 
analysis (Supplementary Table 4). Criteria for exclusion 
were absent or low purity estimations as determined 
by the ABSOLUTE computational method [21] and 
insufficient numbers of subclonal variants identified 
for analysis. Cohort 3 consisted of 10 specimens, from 
six primary and four recurrent tumors. A total of 142 
samples were excluded for the above-mentioned reasons. 
The remaining 10 samples were all primary GBM with 
no history of lower grade glioma, nine of which were 
from the INCB cohort from the Besta Brain Biobank, 
previously published by Wang et al. [5]. The final sample 
was from the SMC cohort from Seoul National University 
Hospital, previously reported by Kim et al. [22]. This 
exercise highlighted the challenges of analyzing disparate 
datasets with absent parameters or collected using varied 
methodology. Approaches varied for both sequencing, 
including platform and depth of coverage, and inference 
of tumor purity. The three cohorts were therefore not 
directly comparable, limiting observations to three 
smaller individual cohorts. The higher rates of exclusion 
to obtain cohorts 2 and 3 may also be reflective of broader 
GBM subtype representation within the cohorts, and the 
potential purity differences between them [19]. 
The effects of including samples to a range of 
minimum purity levels was analyzed in the larger group 
(cohort 2) of primary samples from TCGA (Figure 
5A). Whilst lowering the acceptable minimum purity 
value increased the number of samples included in 
the analysis, it resulted in poorer neutral evolution 
model fits. In comparison, use of purity-adjusted VAFs 
revealed more similar model fits (Mdn = 0.9738, 95% 
CI [0.9647, 0.9824]), with 44% of samples dominated by 
neutral evolutionary dynamics as defined by an R2 value 
of at least 0.98. There seemed to be a shift away from 
characteristically neutral evolution in recurrent samples 
(Mdn = 0.9011, 95% CI [0.8098, 0.9606]). However, 
the analysis was limited to only eight samples with no 
available purity data, and therefore offers little insight. 
Similarly, cohort 3 consisted of 10 specimens with purity 
data enabling adjustment of VAFs prior to assessment of 
a neutral evolution model fit. The R2 model fit values at 
recurrence again were seemingly lower than at diagnosis 
(Mdn = 0.8574, 95% CI [0.7542, 0.9382] at diagnosis vs 
Mdn = 0.7728, 95% CI [0.6685, 0.9032] at recurrence), 
but this difference did not reach statistical significance (p 
= 0.281; Figure 5B). 
Together, these data suggest that there is a stronger 
fit to a neutral evolution model in GBM samples at 
diagnosis, shifting quickly to dynamics reflecting selection 
pressures at recurrence.
DISCUSSION
Our study is unique and adds several new findings to 
the field. We were able to interrogate untreated (n = 3) and 
treated (n = 18) patients and confirmed the dynamic nature 
of genomic alterations in GBM. The instability of genomic 
alterations after GBM recurrence relative to GBM primary 
tumor samples was evident, even in the absence of any 
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therapy. In contrast to data published by others in primary 
GBM [4, 5] and previously described in secondary 
GBM [3], we only observed TMZ treatment-induced 
hypermutation in the recurrent tumor of one patient. 
Consistent with previous reports, the majority of variants 
were of low VAF and occurred in multiple DNA MMR 
genes. MGMT was also methylated in both the primary 
tumor and at recurrence. In contrast to other studies, both 
were IDH wildtype [3, 22] providing one example against 
the notion that the lack of hypermutation in primary GBM 
is due to a fundamental difference between IDH mutant 
(secondary) and IDH wildtype (primary) GBM [23]. 
Furthermore, when closely examining the total number 
and proportions of TMZ-associated variants in each 
dinucleotide context, we could not discern enrichment 
for these TMZ-associated transitions in any patients other 
than the one patient. This suggests a different evolution of 
variants or active repair of such variants in the majority of 
primary GBM after TMZ treatment.
 A perfectly neutral evolution of subclonal variants 
results in a constant allelic frequency of each variant as 
the tumor expands (Figure 6). The growth rate of cells that 
possess one or more variants is no different from cells that 
do not. New variants that arise expand at the same rate 
with no fitness advantage. After therapy at recurrence a 
further shift toward non-neutral modes of evolution was 
observed. A differential response to therapy and treatment-
induced mutagenesis would see some resistant mutant 
subclones expand rapidly while others are eliminated. The 
allelic frequencies of variants therefore would also alter to 
varying degrees.
A limitation of this study was its retrospective nature 
and the unavailability of normal specimens for germline 
analysis from these patients. Four measures were taken 
to overcome this limitation while taking full advantage 
of these matched initial vs. recurrent tumor sets: (1) 
common variants according to the NCBI SNP database 
[24] and 1000 genomes MAF data [25] were excluded 
to limit analyses to probable disease associated variants 
that impact function; (2) deep sequencing was performed 
for only previously identified cancer-associated genes 
with alterations frequently suggestive of gain- or loss-of-
Figure 3: TMZ-induced mutational events were not evident in the majority of samples at recurrence. (A) Boxplot 
representing the distribution of single base substitutions unique to recurrence. The y-axis excludes patient 21 as an outlier with 48 detected 
variants. The mean is shown as a circular symbol and the asterisks highlight outliers. (B) An individual value plot presenting the spread 
of single base substitutions occurring uniquely at recurrence and the frequency of patients in which they occur. Substitutions detected 
in treated patients (including patient 21) and untreated patients are highlighted. (C) Total number of C:G > T:A substitutions and the 
proportion of each dinucleotide context.
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Figure 4: Neutral tumor evolution was evident in untreated GBM, however, a shift away from effectively-neutral 
subclone dynamics was observed after radiochemotherapy. (A) Boxplot presenting the estimated purity of samples determined 
by LUMP analysis. The line of short dashes indicates the 55% purity threshold for inclusion in neutral evolution analyses. (B) The 
cumulative distribution M(f) of subclonal mutations in primary tumors prior to therapy analyzed collectively was linear with the inverse of 
their frequency (1/f) (upper panel) and a shift away from linearity and therefore neutral evolution was evident in tumors after treatment at 
recurrence (lower panel; excludes patient 21 recurrent sample). A stringent R2 > 0.98 defines neutral evolution in these collective analyses. 
(C) Subclonal mutations of individual samples were assessed and the variation between tumors at diagnosis and relapse are presented for 
the 10 paired samples analyzed. R2 goodness-of-fit measures for the neutral evolution model decrease from diagnosis to recurrence in 80% 
of paired samples from the same patient. (D) Boxplot of the R2 goodness-of-fit for the neutral evolution model. Subclonal mutations of 
individual samples were assessed and the variation between tumors at diagnosis and relapse are presented for all samples analyzed. The 
line of short dashes indicates the R2 = 0.98 threshold used to distinguish neutral and non-neutral evolution. A two-way analysis of variance 
was performed using the general linear model for continuous variables and the corresponding p-value is displayed. (E) The cumulative 
distribution M(f) of subclonal mutations in the primary tumor (upper panel) and relapse tumor (lower panel) of patient 21. A switch from 
neutral to non-neutral evolutionary dynamics was apparent between tumors at diagnosis and relapse. 
Oncotarget7853www.impactjournals.com/oncotarget
functions; (3) neutral evolution analysis assessed subclonal 
variants with VAFs of less than 0.25 and therefore the 
potential confounding effects of ploidy and low MAF 
germline variants were avoided; (4) analyses were 
centered around comparing the dynamic mutation profiles 
between the primary tumors and their matched recurrent 
counterparts (i.e. we did not aim to identify novel cancer 
genes). Choice of platform was primarily determined by 
the limited material available for processing. The neutral 
evolution model posits that the expanding tumor randomly 
accumulates a large number of new variants in continually 
smaller subclonal fractions. Distinct variants are identified 
in different regions, however, they follow the same 1/f 
distribution. Whilst a greater breadth of sequencing would 
have facilitated a more thorough assessment of variant 
dynamics, the comprehensive cancer panel provided a 
snapshot view comparing the changes in evolutionary 
dynamics in response to treatment rather than a single 
timepoint. Additionally, a higher read depth provided 
more accurate detection of subclonal variants and ensured 
sufficient coverage even in regions with greater sequence 
complexity. Future prospective studies including germline 
analysis will be needed.
Whilst the size of our cohort was not sufficient to 
detect subtle disease pathway associations at the levels 
of statistical significance we were able to make several 
significant observations. We did observe an increase in 
the number of variants with low VAF (< 0.4) in patients 
with mutated TP53 at recurrence confirming previous 
observations [4]. The variant data presented here have a 
number of implications for patients and future approaches 
to therapy. Whilst there was a clear molecular response 
to therapy with DNA damaging agents, the dynamic and 
rapidly evolving nature of variants in GBM conspires 
to quickly select clonal populations that are resistant to 
these therapies. The majority of patients fail treatment 
quickly and succumb to the disease. The median time to 
recurrence whilst on treatment of our cohort as an example 
was only nine months. These data confirm for those in 
the field that such approaches with treatment modalities 
using DNA damage are highly unlikely to translate to 
long term success in treatment. Additionally, the data are 
also suggestive that single targeted therapies using a one-
dimensional personalized approach are likely to be quickly 
overcome through non-neutral evolutionary selection. 
An alternative approach using sequential interventions 
and a chronic disease therapeutic and management 
paradigm may be one consideration. This study also 
highlights a need for a concerted effort to advance GBM 
research, employing prospectively secured specimens 
Figure 5: Interrogation of publically available datasets also indicates a stronger fit to the neutral evolution model 
in untreated primary tumors. (A) Boxplot of the R2 goodness-of-fit for the neutral evolution model, presenting data from cohort 2. 
The minimum purity level of included samples is categorized below the x-axis and the 93 samples which satisfied inclusion criteria for 
analysis using purity-adjusted VAFs are compared. The line of short dashes indicates the R2 = 0.98 threshold used to distinguish neutral and 
non-neutral evolution and the number of samples greater than this threshold out of the total number analyzed in each category is indicated 
above the dashed line. (B) Boxplot of the R2 goodness-of-fit for the neutral evolution model, presenting data from cohort 3. The line of 
short dashes indicates the R2 = 0.98 threshold. A two-way analysis of variance was performed using the general linear model for continuous 
variables and the corresponding p-value is displayed.
Oncotarget7854www.impactjournals.com/oncotarget
and implementing standardized methodologies and data 
analysis pipelines.
MATERIALS AND METHODS
Biospecimen and data acquisition
Formalin-fixed paraffin-embedded (FFPE) tumor 
samples were obtained from the Royal Melbourne Hospital 
(RMH) and University of Melbourne, Department of 
Surgery Brain Tumor Bank. Tissue was collected after 
informed consent during surgical resection at diagnosis 
and recurrence, and matched clinical data was obtained 
from the Australian Comprehensive Cancer Outcomes 
and Research Database (ACCORD). Specimen use was 
approved by the Melbourne Health Human Research 
Ethics Committee (HREC; 2013.084) and research was 
approved by the Monash Health HREC (1301A), with 
subsequent site approvals by the Deakin University 
(2013–124) and Barwon Health HRECs (13/16).
Additional data on GBM samples from publicly 
available datasets were interrogated for VAF and purity 
information. The NCI Genomic Data Commons (GDC) 
[26] portal was used to access the MuTect masked somatic 
mutation MAF file format of the TCGA-GBM dataset 
(https://gdc-portal.nci.nih.gov/projects/TCGA-GBM, 
download November 2016). ABSOLUTE purity levels 
for the dataset were collated from the cBioPortal for 
Cancer Genomics merged cohort of LGG and GBM data 
file (http://www.cbioportal.org/study?id=lgggbm_tcga_
pub#clinical, download November 2016) [27]. Variant 
frequency and purity data was gathered for a further nine 
samples from the INCB cohort from the Besta Brain 
Biobank, previously published by Wang et al. [5] and 
one sample from the SMC cohort from Seoul National 
University Hospital, originally reported by Kim et al. [22].
DNA extraction
Genomic DNA was extracted from tumor tissue 
using the ReliaPrep™ FFPE gDNA Miniprep System 
(Promega), as directed by the manufacturer. The 
quality of the DNA was assessed using a nanodrop 
spectrophotometer and quantified using a Qubit® 
dsDNA HS Assay kit and a Qubit® 2.0 Fluorometer 
(ThermoFisher). 
Targeted sequencing
Multiplexed targeted sequencing was performed 
using the Ion AmpliSeq™ Comprehensive Cancer Panel 
which interrogates 409 cancer associated genes, utilizing 
16000 primer pairs in four pools. Barcoded libraries were 
prepared using 10 ng of gDNA per primer pool and the 
Ion AmpliSeq™ Library Kit 2.0 (Life Technologies), 
as directed by the manufacturer. Template preparation 
and sequencing was conducted by the MHTP Medical 
Genomics Facility (Melbourne, Australia). Amplified 
libraries were quantified using an Agilent® 2100 
Bioanalyzer and combined equally to a final concentration 
Figure 6: Neutral expansion of variants shifts toward non-neutral modes after therapy. Pictorial representation of the 
neutral expansion of subclones and the linear accumulation of variants M(f) with the inverse of their frequency f. An R2 equal to 1.0 depicts 
precisely neutral evolutionary dynamics. With the applied pressure of therapy subclonal expansion becomes altered and variable. Some 
resistant clones and clones with treatment-induced mutations experience a growth advantage and expand rapidly, while other treatment-
sensitive clones are reduced or eliminated. The allelic frequency of some variants increases at a more rapid rate while others are decreased. 
Non-neutral modes of subclonal variant expansion dominate.
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of 100 pM for template preparation with the Ion PI™ 
Template OT2 200 Kit v3. Libraries were sequenced on an 
Ion Proton™ system using the Ion PI™ Sequencing 200 
kit v3 and four samples (16 libraries) were loaded onto 
each Ion PI™ chip v2.
Data processing and variant identification
For cohort 1, sequencing reads were aligned to the 
Human hg19 reference sequence (Build 37) and variant 
calling was performed using the Ion Torrent Software 
Suite 4.0.2 and the Somatic-Proton-Low Stringency 
Variant Caller Plugin v4.0-r76860. Ion Reporter™ 
Software v4.6 was used for variant annotation 
and functional prediction and the Broad Institute 
Integrative Genomics Viewer (IGV) was used for 
manual visualization and exclusion of some variants. 
On average 21 million mapped reads (range 12.4–28.3 
million) with a mean read length of 108 bp (range 
103–112) were generated and were 99% on-target. 
A mean read depth of 1272 (range 769–1697 reads) 
was achieved with an average of 81% uniformity of 
coverage (range 69–91%). Overall, 89% of bases were 
called with a predicted quality score of at least 20 (Q ≥ 
20), encompassing 2 × 109 bases (range 1.3 × 109–2.7 
× 109 bases). Stringent quality, coverage and frequency 
metrics were applied to detected variants to restrict 
analyses to high confidence variants and eliminate 
possible sequencing artefacts [28]. The filtering criteria 
used selected variant calls with p-values of less than 
0.05, quality scores of at least 20 (Q20), coverage of 
greater than 100 reads, allele read counts of at least 50 
reads, and VAFs of at least 8%. Common variants with a 
minor allele frequency, according to the 1000 genomes 
database, of greater than 5% were also excluded to 
limit analyses to probable disease associated variants 
that impact function. Variants that occurred in more 
than 50% of patients were excluded as likely artefacts. 
The cBioPortal for Cancer Genomics OncoPrinter was 
used to generate OncoPrints of key pathway variants 
[29, 30].
A neutral evolution model was applied to variant 
data as detailed previously [6]. Briefly, the total SNVs 
detected within tumor specimens, limited to samples 
with less than or equal to 45% normal contamination as 
determined by leukocyte unmethylation to infer tumor 
purity (LUMP) analysis and variants with purity-adjusted 
allele frequencies greater than 0.10 and less than 0.25, 
encompassing subclonal variants reliably detected by 
high-throughput sequencing, were used to fit the model. 
Therefore clonal events and the potential confounding 
effects of ploidy and low MAF germline variants, 
which would occur at VAFs greater than 0.25, were 
eliminated. A stringent threshold of R2 > 0.98 was used 
for defining the goodness-of-fit to the neutral evolution 
model. In samples with fewer than 10 variants, results 
were scrutinized to ensure that a single outlying data 
point did not heavily influence the slope of the fitted 
line and alter the detection of neutral or non-neutral 
evolution. Due to the targeted nature of this high-depth 
sequencing analysis, fewer subclonal variants available 
to fit the model may undercall neutrality when individual 
specimens are analyzed [6]. Assessment of publicly 
available data was limited to samples with less than or 
equal to 45% normal contamination as determined by 
ABSOLUTE purity values. Due to the lower depth of 
sequencing, only samples with a minimum count of 12 
subclonal variants with purity-adjusted allele frequencies 
greater than or equal to 0.10 or less than 0.25 were 
considered. 
Consideration of SIFT [11] and PROVEAN [12] 
scores was used for the prediction of the functional impact 
of exonic variants. 
Variant validation
A semi-selected validation approach was 
undertaken, focusing on coding variants in genes involved 
in the key signaling pathways altered in GBM. In order to 
be reliably detected by Sanger sequencing only variants 
with an allele frequency greater than 20% were sequenced 
(primer details Supplementary Table 5). These totaled 46 
variants, including 36 SNVs and 10 small insertions and 
deletions (INDELs) and involved the sequencing of 138 
out of the 5357 (2.6%) variants detected overall. Similar 
to other studies [3, 4, 31], validation rates for SNVs and 
INDELs were 94% and 50% respectively, achieving an 
overall variant validation rate of 85%.
DNA methylation analysis of MGMT
Genomic DNA was prepared for analysis using 
the MethyEasy™ Bisulphite Kit (Genetic signatures) 
and subsequent processing was undertaken by The 
Centre for Applied Genomics, The Hospital for Sick 
Children (Toronto, Canada) as per manufacturer’s 
instructions. Four samples were replicated on dual 
array processing runs to assess the reproducibility of 
the arrays. Data for each replicate sample correlated 
well (average R2 = 0.952; range 0.904–0.986). The 
methylation status of MGMT was determined by 
assessing both the beta value determined for probe 
cg12981137, which detects the level of methylation at 
a CpG site within a distinct region of MGMT exon 1 
found to be most strongly associated with expression 
[32], and the mean beta value across all 12 available 
probes corresponding to sites in the promoter region of 
MGMT. Samples with a beta value above a threshold of 
0.2 as described previously [33] for probe cg12981137 
that also correlated with a mean beta value above this 
threshold across all 12 sites within the promoter region 
were considered methylated. 
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Leukocytes unmethylation to infer tumor purity 
analysis
Due to the absence of matched normal DNA, 
LUMP analysis was used to assess tumor purity of 
samples in cohort 1 as previously described [19]. LUMP 
estimations were based on the average methylation 
levels of 39 of the informative CpG sites. Probes 
cg00240653, cg02997560, cg03436397, cg26427109 
and cg05199874 were excluded from the analysis as the 
detection p-value for these was not below a threshold 
(T) of 0.05.
Statistics
All statistical analyses were conducted using 
the Minitab® v17.1.0 software package. A two-way 
analysis of variance was performed using the general 
linear model for continuous variables. Initially a 
test for the interaction of factors was included. If no 
significant interaction was identified the test was re-
run without the interaction terms. The response, the 
number of variants, was examined against and adjusted 
for treatment and sample type or whether a variant 
was shared or unique between matched samples. The 
F-value F(df effect, df error) and T-value t(df) are 
also reported where appropriate. Similar analyses 
were undertaken to examine the differences in variant 
numbers with specific single base substitutions and 
between neutral evolution R2 model fit values. Post-hoc 
pairwise comparisons were conducted using the Tukey 
method. The Grubbs’ test was used to detect outliers 
in the data set. The null hypothesis that there were no 
outliers was rejected at the 0.05 significance level. 
The differences between the number of tumors 
adhering to the neutral evolution model at diagnosis 
and relapse were also assessed using a one-sample t-test 
against the threshold value of R2 = 0.98. A similar analysis 
was undertaken to compare the mean R2 model fit values 
of each group to R2 = 0.96. For all analyses a p-value less 
than or equal to 0.05 was considered to indicate statistical 
significance.
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